Citations

Clear

6273 citation(s) found for "To, Andrew".

2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative
Dejaco, Christian , Singh, Yogesh Preet , Perel, Pablo , Hutchings, Andrew , Camellino, Dario , Mackie, Sarah , Abril, Andy , Bachta, Artur , Bálint, Péter, Barraclough, Kevin, Bianconi, L., Buttgereit, Frank , Carsons, Steven E. , Ching, Daniel , Cid, María C. , Cimmino, Marco A. , Diamantopoulos, Andreas P. , Docken, William P., Duftner, Christina , Fashanu, Billy, Gilbert, Kate, Hildreth, Pamela, Hollywood, Jane, Jayne, David , Lima, Manuella , Maharaj, Ajesh B. , Mallen, Christian , Martínez‐Taboada, Víctor M. , Maz, Mehrdad , Merry, Steven, Miller, Jean , Mori, Shunsuke , Nordborg, Elisabeth, Nott, Jennifer, Padbury, Hannah, Pease, Colin, Salvarani, Carlo , Schirmer, Michael , Schmidt, Wolfgang , Tronnier, David, Wagner, Alexandre, Whitlock, Madeline, Matteson, Eric L. , Merry, Stephen , Souza, Alexandre Wagner Silva de , Neill, Lorna M. , Salvarani, Carlo , Spiera, Robert , Wagner, Alexandre, Dasgupta, Bhaskar , Dejaco, Christian , Merry, Stephen P , Mackie, Sarah Louise , Jayne, David , Buttgereit, Frank , Singh, Yogesh Preet , de Souza, Alexandre Wagner Silva

Mayo Clinic

Arthritis & Rheumatology | September 10, 2015 | Volume: 67 | Issue: 10 | Pages: 2569-2580

10.1002/art.39333 | PMID 26352874 Get It

Abstract Therapy for polymyalgia rheumatica (PMR) varies widely in clinical practice as international recommendations for PMR treatment are not currently available. In this paper, we report the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of PMR. We used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology as a framework for the project. Accordingly, the direction and strength of the recommendations are based on the quality of evidence, the balance between desirable and undesirable effects, patients’ and clinicians’ values and preferences, and resource use. Eight overarching principles and nine specific recommendations were developed covering several aspects of PMR, including basic and follow‐up investigations of patients under treatment, risk factor assessment, medical access for patients and specialist referral, treatment strategies such as initial glucocorticoid (GC) doses and subsequent tapering regimens, use of intramuscular GCs and disease modifying anti‐rheumatic drugs (DMARDs), as well as the roles of non‐steroidal anti‐rheumatic drugs and non‐pharmacological interventions. These recommendations will inform primary, secondary and tertiary care physicians about an international consensus on the management of PMR. These recommendations should serve to inform clinicians about best practices in the care of patients with PMR.
The Metastatic Spine Disease Multidisciplinary Working Group Algorithms
Robinson, Clifford G. , Meyer, Jeffrey , Gangi, Afshin , Callstrom, Matthew R. , Chao, Samuel T. , Tine, Brian Andrew Van, Bruel, Brian M., Long, Jeremiah R. , Timmerman, Robert , Buchowski, Jacob M. , Jennings, Jack W. , Wallace, Adam N, Tran, Nam D, Van Tine, Brian A, Long, Jeremiah, Timmerman, Robert D, Wallace, Adam N. , Tran, Nam , Morris, Jonathan M. , Robinson, Clifford

Mayo Clinic

The Oncologist | September 10, 2015 | Volume: 20 | Issue: 10 | Pages: 1205-1215

10.1634/theoncologist.2015-0085 | PMID 26354526 Get It

AbstractThe Metastatic Spine Disease Multidisciplinary Working Group consists of medical and radiation oncologists, surgeons, and interventional radiologists from multiple comprehensive cancer centers who have developed evidence- and expert opinion-based algorithms for managing metastatic spine disease. The purpose of these algorithms is to facilitate interdisciplinary referrals by providing physicians with straightforward recommendations regarding the use of available treatment options, including emerging modalities such as stereotactic body radiation therapy and percutaneous tumor ablation. This consensus document details the evidence supporting the Working Group algorithms and includes illustrative cases to demonstrate how the algorithms may be applied.Implications for Practice:The Metastatic Spine Disease Multidisciplinary Working Group algorithms can facilitate interdisciplinary referrals by providing physicians with straightforward recommendations regarding available treatment options, including emerging modalities such as stereotactic body radiation therapy and percutaneous tumor ablation.
Heritability of young‐ and old‐onset ischaemic stroke
Bluher, Andrew E. , Devan, William J., Holliday, E. G., Nalls, Mike A. , Parolo, Silvia , Bione, Silvia , Giese, Anne‐Katrin , Boncoraglio, Giorgio B. , Maguire, Jane , Müller‐Nurasyid, Martina , Gieger, Christian , Rolfs, A., Kittner, Steven J. , Mitchell, Braxton D. , O’Connell, Jeff, Holliday, E. G., Meschia, James F. , Rosand, Jonathan M. , Cheng, Y.‐C., Mitchell, Braxton D

Mayo Clinic

European Journal of Neurology | September 3, 2015 | Volume: 22 | Issue: 11 | Pages: 1488-1491

10.1111/ene.12827 | PMID 26333310 Get It

Background and purposeAlthough the genetic contribution to stroke risk is well known, it remains unclear if young‐onset stroke has a stronger genetic contribution than old‐onset stroke. This study aims to compare the heritability of ischaemic stroke risk between young and old, using common genetic variants from whole‐genome array data in population‐based samples.MethodsThis analysis included 4050 ischaemic stroke cases and 5765 controls from six study populations of European ancestry; 47% of cases were young‐onset stroke (age < 55 years). To quantify the heritability for stroke risk in these unrelated individuals, the pairwise genetic relatedness was estimated between individuals based on their whole‐genome array data using a mixed linear model. Heritability was estimated separately for young‐onset stroke and old‐onset stroke (age ≥ 55 years).ResultsHeritabilities for young‐onset stroke and old‐onset stroke were estimated at 42% (±8%, P < 0.001) and 34% (±10%, P < 0.001), respectively.ConclusionsOur data suggest that the genetic contribution to the risk of stroke may be higher in young‐onset ischaemic stroke, although the difference was not statistically significant.
Integration of extracellular RNA profiling data using metadata, biomedical ontologies and Linked Data technologies
Subramanian, Sai Lakshmi , Alexander, Roger P. , Cheung, Kei‐Hoi, Laurent, Louise C. , Roberts, Lewis R. , Roth, Matthew E. , Rozowsky, Joel , Su, Andrew I. , Gerstein, Mark , Kitchen, Robert , Carter, Bob S. , Laurent, Louise C , Pico, Alexander R. , Milosavljevic, Aleksandar , Roberts, Lewis R , Gerstein, Mark

Mayo Clinic

Journal of Extracellular Vesicles | August 28, 2015 | Volume: 4 | Issue: 1 | Pages: No page available

10.3402/jev.v4.27497 | PMID 26320941 Get It

The large diversity and volume of extracellular RNA (exRNA) data that will form the basis of the exRNA Atlas generated by the Extracellular RNA Communication Consortium pose a substantial data integration challenge. We here present the strategy that is being implemented by the exRNA Data Management and Resource Repository, which employs metadata, biomedical ontologies and Linked Data technologies, such as Resource Description Framework to integrate a diverse set of exRNA profiles into an exRNA Atlas and enable integrative exRNA analysis. We focus on the following three specific data integration tasks: (a) selection of samples from a virtual biorepository for exRNA profiling and for inclusion in the exRNA Atlas; (b) retrieval of a data slice from the exRNA Atlas for integrative analysis and (c) interpretation of exRNA analysis results in the context of pathways and networks. As exRNA profiling gains wide adoption in the research community, we anticipate that the strategies discussed here will increasingly be required to enable data reuse and to facilitate integrative analysis of exRNA data.
Biomarkers in Acute Decompensated Heart Failure
Rosenbaum, Andrew , Miller, Wayne L.

Mayo Clinic

Clinical Medicine Insights: Therapeutics | August 27, 2015 | Volume: 7 | Issue: No issue available | Pages: No page available

10.4137/cmt.s18476 Get It

Acute decompensated heart failure (ADHF) is a prominent condition whose frequency is increasing, especially in the context of an aging population. The ability to discern the cause of undifferentiated dyspnea in acute presentations is an increasing struggle. In this review, we seek to explore the various biomarkers that have been studied for the diagnosis of ADHF and their respective clinical utilities as the most recent data would suggest. Natriuretic peptides, galectin-3, soluble ST2, adrenomedullin, cardiac troponin-T, neutrophil gelatinase-associated lipocalin, and copeptin are reviewed. Of these biomarkers, natriuretic peptides are the most thoroughly evaluated and show the most promise for diagnosis or exclusion of acute heart failure, though other biomarkers can add significant utility in the form of prognostication.
Abstract POSTER-THER-1409: Targeting p53-FoxM1 axis in ovarian cancer
Cheng, Lihua, Minn, Kay, Waggoner, Magdalena, Parelkar, Nikhil K., Jokar, Iman, Vielhauer, George, Madan, Rashna , Shridhar, Viji , Chien, Jeremy , Zhang, Xuan , Godwin, Andrew K. , Chien, Jeremey

Mayo Clinic

Clinical Cancer Research | August 19, 2015 | Volume: 21 | Issue: 16_Supplement | Pages: POSTER-THER-1409-POSTER-THER-140

10.1158/1557-3265.ovcasymp14-poster-ther-1409 Get It

Abstract FoxM1, a member of the Forkhead transfection factors, has been found to be overexpressed in many human cancers including ovarian cancer. Although FoxM1 is known to be downregulated by p53, the molecular mechanisms are not well characterized. In this study, we used the MDM2 inhibitor Nutlin-3 as a tool to modulate p53 expression and investigated the mechanism by which p53 regulates FoxM1 expression in ovarian cancer cells. We observed that Nutlin-3 upregulated p53 protein and downregulated FoxM1 mRNA and protein levels in ovarian cancer cell lines with wild type TP53, but not in cell lines with mutant TP53. This effect was at least partially blocked by cycloheximide or actinomycin D, indicating a transcription- and translation-dependent mechanism. Pulse-chase studies revealed that downregulation of FoxM1 by Nutlin-3 is due to enhanced FoxM1 mRNA decay. Knockdown of p53 using shRNAs abrogated the suppression of FoxM1 expression by Nutlin-3, indicating a p53-dependent mechanism. Furthermore, silencing of FoxM1 by shRNAs in ovarian cancer cells with or without wild-type TP53 led to a significant decrease in cell proliferation. The FoxM1 inhibitor, thiostrepton, induces cytotoxicity in ovarian cancer cell lines and enhances sensitivity to cisplatin in these cells. Thiostrepton downregulates FoxM1 expression in several ovarian cancer cell lines and enhances sensitivity to carboplatin in vivo. Finally, FoxM1 expression is elevated in nearly all (47/48) ovarian tumors. In summary, the present study provides novel evidence that p53 downregulates FoxM1 in ovarian cancer cells at least in part by destabilizing FoxM1 mRNA and that FoxM1 may be targeted for therapeutic benefits in ovarian cancer. Citation Format: Xuan Zhang, Lihua Cheng, Kay Minn, Magdalena Waggoner, Nikhil K. Parelkar, Iman Jokar, George A. Vielhauer, Rashna Madan, Andrew K. Godwin, Viji Shridhar,, Jeremy Chien. Targeting p53-FoxM1 axis in ovarian cancer [abstract]. In: Proceedings of the 10th Biennial Ovarian Cancer Research Symposium; Sep 8-9, 2014; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(16 Suppl):Abstract nr POSTER-THER-1409.
First seizure management
Cascino, Gregory D. , Cole, Andrew J.

Mayo Clinic

Neurology Clinical Practice | August 17, 2015 | Volume: 5 | Issue: 4 | Pages: 278-280

10.1212/cpj.0000000000000151 | PMID 26336628 Get It

Anesthesia and Poliomyelitis: A Matched Cohort Study
Alstine, Luke W. Van, Gunn, Paul W., Schroeder, Darrell R. , Hanson, Andrew C. , Sorenson, Eric J. , Martin, David P. , Van Alstine, Luke W, Schroeder, Darrell

Mayo Clinic

Anesthesia & Analgesia | August 14, 2015 | Volume: 122 | Issue: 6 | Pages: 1894-1900

10.1213/ane.0000000000000924 | PMID 26273744 Get It

BACKGROUND: Poliomyelitis is a viral infectious disease caused by 1 of the 3 strains of poliovirus. The World Health Organization launched an eradication campaign in 1988. Although the number of cases of poliomyelitis has drastically declined, eradication has not yet been achieved, and there are a substantial number of survivors of the disease. Survivors of poliomyelitis present a unique set of challenges to the anesthesiologist. The scientific literature regarding the anesthetic management of survivors of poliomyelitis, however, is limited and primarily experiential in nature. Using a retrospective, matched cohort study, we sought to more precisely characterize the anesthetic implications of poliomyelitis and to determine what risks, if any, may be present for patients with a history of the disease. METHODS: Using the Mayo Clinic Life Sciences System Data Discovery and Query Builder, study subjects were identified as those with a history of paralytic poliomyelitis who had undergone major surgery at Mayo Clinic Rochester between 2005 and 2009. For each case, 2 sex- and age-matched controls that underwent the same surgical procedure during the study period were randomly selected from a pool of possible controls. Medical records were manually interrogated with respect to demographic variables, comorbid conditions, operative and anesthetic course, and postoperative course. RESULTS: We analyzed 100 cases with 2:1 matched controls and found that the peri- and postoperative courses were very similar for both groups of patients. Pain scores, postanesthesia care unit admission, length of postanesthesia care unit stay, intensive care unit admission, length of intensive care unit stay, and initial extubation location were not significantly different between the 2 groups. Looking at pulmonary complications in our primary outcome, there was no significant difference between the 2 groups (17% vs 14% for polio versus control, respectively; conditional logistic regression odds ratio = 1.5; 95% confidence interval, 0.7–3.3; P = 0.33). In addition, no difference was noted in those requiring a code or rapid response team intervention (4% vs 3% for polio versus control; P = 0.46) and the 30-day mortality rate was also not significantly different, with 2% of polio patients dying compared with 3% of controls ( P = 0.79). The analysis of the primary outcome was repeated for the subset of patients with a history of poliomyelitis who had persistent neurologic deficits preoperatively ( n = 36) and their matched controls ( n = 72). In this subset analysis, there were 4 (11%) polio patients and 8 (11%) control patients who experienced pulmonary complications (conditional logistic regression odds ratio = 1.00; 95% confidence interval, 0.27–3.72; P = 1.00). The percentage of patients experiencing specific pulmonary complications of interest was similar between groups (postoperative mechanical ventilation: 6% vs 8% for polio and control patients, respectively; prolonged mechanical ventilation: 0% vs 1%; reintubation: 8% vs 4%; pulmonary infection: 6% vs 6%; and aspiration: 0% vs 1%). CONCLUSIONS: This study suggests that patients with a history of poliomyelitis do not seem to have an increased risk of pulmonary complications in the perioperative period. However, an odds ratio as great as 3.3-fold may be present.
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41)
Jackson, Amie E., Mian, Michael , Kalpadakis, Christina , Pangalis, Gerassimos A. , Stathis, Anastasios , Porro, Elena, Conconi, Annarita , Cortelazzo, Sergio, Gaïdano, Gianluca , Guillermo, Armando López, Martinelli, Giovanni , Thiéblemont, Catherine , McPhail, Ellen D. , Copie‐Bergman, Christiane , Jack, Andrew , Campo, Elı́as , Mazzucchelli, Luca, Ristow, Kay M., Cavalli, Franco , Nowakowski, Grzegorz S. , Zucca, Emanuele , Johnson, Peter W, Martelli, Maurizio , Copie-Bergman, Christiane, Pileri, Stefano A, Ristow, Kay, Johnson, Peter , Martelli, Maurizio , McPhail, Ellen Darcy , Pileri, Stefano , Habermann, Thomas M. , Campo, Elías , Gaidano, Gianluca , Zucca, Emanuele

Mayo Clinic

The Oncologist | August 13, 2015 | Volume: 20 | Issue: 10 | Pages: 1149-1153

10.1634/theoncologist.2015-0180 | PMID 26268740 Get It

Abstract Background. The salivary gland is one of the most common sites involved by nongastric, extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT). A large series of patients with long-term follow-up has not been documented. This multicenter, international study sought to characterize the clinical characteristics, treatment, and natural history of salivary gland MALT lymphoma. Methods. Patients with biopsy-confirmed salivary gland MALT lymphoma were identified from multiple international sites. Risk factors, treatment, and long-term outcomes were evaluated. Results. A total of 247 patients were evaluated; 76% presented with limited-stage disease. There was a history of autoimmune disorder in 41%, with Sjögren disease being the most common (83%). Fifty-seven percent of patients were initially treated with local therapy with surgery, radiation, or both; 37 of patients were treated with systemic therapy initially, with 47% of those receiving rituximab; and 6% of patients were observed. The median overall survival (OS) was 18.3 years. The median progression-free survival (PFS) following primary therapy was 9.3 years. There was no difference in the outcomes between patients receiving local or systemic therapy in first-line management. On multivariate analysis, age &lt;60 years and low to intermediate international prognostic index were associated with improved OS and PFS; Sjögren disease was associated with improved OS. Conclusion. Salivary gland MALT lymphoma has an excellent prognosis regardless of initial treatment, and patients with Sjögren disease have improved survival. Risks for long-term complications must be weighed when determining initial therapy. Implications for Practice: Patients with salivary gland extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) have an excellent prognosis, particularly those with associated Sjögren's disease. A wide range of available therapies may provide similar durable rates of disease control and survival. Therefore, an important goal in selection of therapy should be to minimize morbidity from treatment. When determining initial therapy for these patients, practitioners should consider the potential side effects and long-term toxicities of treatment.
Risk and Outcomes of Substance Use Disorder among Anesthesiology Residents
Berge, Keith H., Harman, Ann E., Hanson, Andrew C. , Schroeder, Darrell R. , Warner, David O. , Sun, Huaping, Schroeder, Darrell

Mayo Clinic

Anesthesiology | August 11, 2015 | Volume: 123 | Issue: 4 | Pages: 929-936

10.1097/aln.0000000000000810 | PMID 26263431 Get It

AbstractAbstract In a nested, matched case-cohort design of 384 anesthesia residents who developed substance use disorder (SUD) and 768 controls who did not, receiving medical education in the United States, but not anesthesia knowledge early in residency, was associated with risk of developing SUD. By the end of follow-up, 54 anesthesiology residents (14.1%) with SUD and 10 controls (1.3%) were dead. Those with SUD were 15-, 10-, and 7-fold more likely to not complete residency, to not become board certified, or have adverse medical licensure actions, respectively. Background: The goal of this work is to evaluate selected risk factors and outcomes for substance use disorder (SUD) in physicians enrolled in anesthesiology residencies approved by the Accreditation Council for Graduate Medical Education. Methods: For each of 384 individuals with evidence of SUD while in primary residency training in anesthesiology from 1975 to 2009, two controls (n = 768) who did not develop SUD were identified and matched for sex, age, primary residency program, and program start date. Risk factors evaluated included location of medical school training (United States vs. other) and anesthesia knowledge as assessed by In-Training Examination performance. Outcomes (assessed to December 31, 2013, with a median follow-up time of 12.2 and 15.1 yr for cases and controls, respectively) included mortality and profession-related outcomes. Results: Receiving medical education within the United States, but not performance on the first in-training examination, was associated with an increased risk of developing SUD as a resident. Cases demonstrated a marked increase in the risk of death after training (hazard ratio, 7.9; 95% CI, 3.1 to 20.5), adverse training outcomes including failure to complete residency (odds ratio, 14.9; 95% CI, 9.0 to 24.6) or become board certified (odds ratio, 10.4; 95% CI, 7.0 to 15.5), and adverse medical licensure actions subsequent to residency (hazard ratio, 6.8; 95% CI, 3.8 to 12.2). As of the end of follow-up, 54 cases (14.1%) were deceased compared with 10 controls (1.3%); 28 cases and no controls died during residency. Conclusion: The attributable risk of SUD to several adverse outcomes during and after residency training, including death and adverse medical license actions, is substantial.